Table 2.
Base-case results a .
| Cost (US$) | Time (day) | Monetary loss b (US$) | Patients with appropriate FDA-approved therapies | |
|---|---|---|---|---|
| “Tissue-first” NGS approach | 2354 (1963 to 2779) | 15.3 (12.9 to 18.0) | 4745 (4010 to 5480) | 99.4% (98.9 to 99.8%) |
| “Complementary” NGS approach | 4795 (4085 to 5453) | 12.7 (10.8 to 14.9) | 6778 (5923 to 7600) | 99.4% (98.9 to 99.8%) |
| “Plasma-first” NGS approach | 4316 (3659 to 4946) | 17.2 (14.7 to 20.1) | 7006 (6047 to 7964) | 99.4% (98.9 to 99.8%) |
a
Values in parentheses denote the 95% prediction intervals.
b
Monetary loss included testing and productivity costs, latter was the product of turnaround time and average wage.
FDA, U.S. Food and Drug Administration; NGS, next generation sequencing.